◆英語タイトル:BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C5006
◆発行会社(調査会社):
GlobalData
◆発行日:2018年9月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
BioInvent International AB (BINV) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
BioInvent International AB (BioInvent) focuses on the discovery and development of antibody drugs for the treatment of cancer. The company uses n-CoDeR, its inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company’s pipeline portfolio comprises THR-317, an antibody to treat patients with diabetic macular edema; BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and TB-403 being developed for the treatment of medulloblastoma. The company partners with several leading pharmaceutical companies including Daiichi Sankyo, Bayer Pharma and Mitsubishi Tanabe Pharma for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.
BioInvent International AB Key Recent Developments
Jul 09,2018: The Japanese patent office intends to grant BioInvent patent relevant to its F.I.R.S.T. platform
Apr 12,2018: BioInvent recruits Martin Welschof as new CEO
Jan 30,2018: BioInvent Reports Net Sales Of SEK 45 Million In 2017
Oct 24,2017: The CEO of BioInvent Michael Oredsson will resign at the end of the year
Jul 26,2017: BioInvent Interim Report 1 January – 30 June 2017
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
BioInvent International AB – Key Facts 5
BioInvent International AB – Key Employees 6
BioInvent International AB – Key Employee Biographies 7
BioInvent International AB – Major Products and Services 8
BioInvent International AB – History 9
BioInvent International AB – Company Statement 13
BioInvent International AB – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
Company Overview 15
BioInvent International AB – Business Description 16
BioInvent International AB – Corporate Strategy 17
BioInvent International AB – SWOT Analysis 18
SWOT Analysis – Overview 18
BioInvent International AB – Strengths 18
BioInvent International AB – Weaknesses 19
BioInvent International AB – Opportunities 20
BioInvent International AB – Threats 21
BioInvent International AB – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
BioInvent International AB, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Jul 09, 2018: The Japanese patent office intends to grant BioInvent patent relevant to its F.I.R.S.T. platform 32
Apr 12, 2018: BioInvent recruits Martin Welschof as new CEO 33
Oct 24, 2017: The CEO of BioInvent Michael Oredsson will resign at the end of the year 34
Jul 26, 2017: BioInvent Interim Report 1 January – 30 June 2017 35
May 17, 2017: BioInvent Interim Report 39
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46
List of Tables
BioInvent International AB, Key Facts 5
BioInvent International AB, Key Employees 6
BioInvent International AB, Key Employee Biographies 7
BioInvent International AB, Major Products and Services 8
BioInvent International AB, History 9
BioInvent International AB, Subsidiaries 14
BioInvent International AB, Key Competitors 22
BioInvent International AB, Ratios based on current share price 23
BioInvent International AB, Annual Ratios 24
BioInvent International AB, Annual Ratios (Cont...1) 25
BioInvent International AB, Interim Ratios 27
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
BioInvent International AB, Recent Deals Summary 31
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45
List of Figures
BioInvent International AB, Performance Chart (2013 - 2017) 26
BioInvent International AB, Ratio Charts 28
BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
BioInvent International AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30